Phase
Startup
Asgard Therapeutics
Asgard Therapeutics was founded in 2018 as a spin-off from Lund University aiming to advance cancer immunotherapies by developing a paradigm-shifting gene therapy – TrojanDC. Driven by the urgent need for new cost-effective immunotherapies consistently effective in a broad range of patients, Asgard is developing the world’s first cancer immunotherapy based on direct cell reprogramming, forcing cancer cells to become immunogenic and unleashing the immune system against cancer.
Cristiana Pires holds a degree in Pharmaceutical Sciences and PhD in Cell Reprogramming. She founded Asgard Therapeutics in 2018 together with the other two inventors of TrojanDC, Associate Professor Filipe Pereira and Fábio Rosa, MSc. Now, by combining her pharmaceutical and scientific background with entrepreneurship experience, Cristiana is motivated to bring TrojanDC to the patients.
Did you know?
Asgard’s scientific founders are from Portugal and decided to honor the Swedish affiliation by choosing a name inspired by the Norse Mythology.
Non-invasive cardiac pressure monitoring device
Accelerated drug development in oncology
Simplify medicine information through digital services
Cancer immunotherapies based in cell reprogramming
Behavioral coaching app
Antibiotic-free treatment for vaginal bacterial infections
Individualised information of the intestinal flora
Digital service for patients
Digital tool for meeting an allergy doctor
Mobile systems for movement analysis
Innovative solutions for better health care
Medical device that reduces pain during vein operation
Prebiotics for irritable bowel syndrome
Digital assistive device for post-surgical rehabilitation
Healthtech for children with eating challenges
Nanotechnology based infection control
Therapeutics after stroke
Equipment that improves the function of cultivated cells
Male-Factor Infertility Diagnostics
Medtech solution for preventing pressure ulcers
Gene editing analysis solution
Stroke detection device
Wound treatment gel
